嵌入于子中胃抵抗性自我乳化颗粒中的甲基醇的生物可用性
Radoslava Kristofova1,2, Karin Zitterl-Eglseer3, Fardad Firooznia4
1Department of Digestive Tract Physiology, Institute of Animal Physiology, Centre of Biosciences, Slovak Academy of Sciences, Soltesovej 4-6, 040 01 Kosice, Slovakia.
Animals : an open access journal from MDPI
|November 27, 2025
概括
胃耐药蒂摩尔颗粒通过向肠道吸收,增强了口服生物可用性. 胸腺醇在组织中积累,证明有效的输送和防止胃退化.
科学领域:
- 药理动力学和药物输送方法
- 动物营养 动物营养
- 胃肠道生理学 胃肠道生理学
背景情况:
- 提摩尔是一种天然化合物,具有潜在的治疗益处,但其口服生物利用性较差.
- 有针对性的药物输送系统对于提高口服化合物的疗效至关重要.
- 胃耐药配方可以保护活性成分免于在胃中降解,并促进肠道吸收.
研究的目的:
- 在子中评估通过胃耐药的自我乳化颗粒输送的提摩尔的口服生物可用性和药理动力学特征.
- 评估小肠中醇的目标释放和吸收.
- 为了研究醇在各种组织中的积累和降解概况.
主要方法:
- 48只子被分为对照组和实验组,后者接受了装有甲基醇的胃耐药颗粒.
- 在服用和戒断期间,测量了醇度在血和十二指肠壁 (DW) 中.
- 在脏,脂肪,脏和肌肉中分析了醇的组织分布和积累.
主要成果:
- 与血相比,甲基醇度在十二指壁中显著更高.
- 在给药过程中,在血和十二指甲状腺壁胆固醇度之间观察到强烈的正相关性.
- 药物注射后在脏和脂肪组织中观察到高效的提摩尔积累,在药物注射结束后,血中的水平低于检测极限.
结论:
- 胃耐药的自我乳化颗粒通过确保在小肠中有针对性的释放,有效地提高了提摩尔的口服生物可用性.
- 该配方保护提摩尔免受胃部降解,并促进其在主要吸收部位的吸收.
- 蒂摩尔证明了有效的组织积累,这表明潜在的持续治疗效果.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
481
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
481
01:27Bioavailability Enhancement: Drug Permeability Enhancement
176
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
176
01:21Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
3.0K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
3.0K
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
289
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
289
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
139
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139